September 7th 2025
Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery
Employers Express Their Concerns With Cancer Care at the COA Summit
How Can Practices Seek Success With Oncology Payment Reform?
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers
Breast Cancer Death Rates Drop, but Racial Disparities Linger